NR1H4 and metabolic dysfunction-associated steatohepatitis: FXR agonism has shown benefit in several preclinical models of NAFLD/NASH (see previous works22, 28 and references therein for details) attributed its metabolic actions as well as its immunomodulatory and anti‐inflammatory effects.